Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback